Achieve Life Sciences (ACHV) Operating Expenses (2010 - 2026)

Achieve Life Sciences has disclosed Operating Expenses across 17 years of filings, most recently posting $10.5 million for Q1 2026.

• Quarterly Operating Expenses fell 18.85% year-over-year to $10.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.4 million (up 14.07% YoY) and the FY2025 annual result came in at $54.9 million, up 40.47% from the prior year.
• Operating Expenses retreated to $10.5 million in Q1 2026, from $14.7 million in the prior quarter.
• Over five years, Operating Expenses peaked at $14.7 million in Q4 2025 and troughed at $4.4 million in Q4 2023.
• A 5-year average of $10.1 million and a median of $10.5 million in 2026 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2023 — Operating Expenses plunged 59.62% — and 2024, when it soared 177.93%.
• Tracing ACHV's Operating Expenses over 5 years: stood at $10.9 million in 2022, then slumped by 59.62% to $4.4 million in 2023, then surged by 177.93% to $12.2 million in 2024, then increased by 20.84% to $14.7 million in 2025, then fell by 28.97% to $10.5 million in 2026.
• Business Quant data shows ACHV's Operating Expenses at $10.5 million in Q1 2026, $14.7 million in Q4 2025, and $14.7 million in Q3 2025.